pathological changes of different treatments, we euthanized mice at 1 or 4 h after injection. Blood was collected and serum isolated within 2 h and stored at 280˚C. Organs were fixed in 4% (w/v) paraformaldehyde for 24 h and then stored in 70% (v/v) ethanol until embedded and sectioned.
Tissue culture
EAhy926 (human endothelial) cell line was cultured in DMEM (Sigma) supplemented with 20% (v/v) FBS (Sigma). HUVECs were isolated as described previously (28) and cultured in DMEM supplemented with 20% (v/v) FBS and 5 ng/ml epidermal growth factor (Invitrogen) for use within three passages.
Reagents
Human CRP (Merck) was extensively dialyzed and concentrated. After confirmation of the pentamer form of each protein by HPLC gel filtration, CRP at final concentrations of 1, 2, or 4 mg/ml was stored at 280˚C. Antihistone single-chain variable fragment (ahscFv) was expressed in E. coli and purified, as previously described, with demonstration of antihistone specificity (27) . LPS contamination was monitored using E-Toxate reagents (Sigma). Recombinant histones (New England Biolabs) and calf thymus histones (Roche) were also monitored using E-Toxate.
Histone cytotoxicity assay
A propidium iodide (PI) method was used, as previously described (29) . In brief, EAhy926 cells were grown to 70-90% confluence and treated with histones or histones preincubated with CRP or activated protein C for 30 min in DMEM supplemented with 2% (v/v) FBS. After 1h of incubation, the medium was removed to a fresh tube, and the remaining cells were detached using Versene and transferred to the same tube. The cells were pelleted, washed, and fixed in 70% (v/v) ethanol for 30 min at 220˚C before staining with 20 mg/ml PI. Flow cytometric analysis of PI-stained damaged nuclei results in a broad peak of hypodiploid particles, clearly separated from the distinct diploid DNA peak of viable cells.
Quantification of circulating histones, histone-CRP complexes, CRP, soluble thrombomodulin, and thrombin-antithrombin A Cell Death Detection ELISA PLUS kit (Roche Diagnostics) was modified for measuring histone-CRP complexes in serum by replacing anti-DNA Ab with HRP-conjugated anti-CRP mAb (Abcam). ELISA kits were also used to determine CRP (Diamed), soluble thrombomodulin (sTM), and thrombin-antithrombin (TAT; Cusabio Biotech) levels in serum. Each sample was performed in duplicate. Histone H3 in plasma were detected by Western blotting using anti-histone H3 Ab (Abcam) and calculated using human recombinant histone H3 protein as standard.
Permeability assay
The in vitro permeability was analyzed in a dual-chamber system using Evans blue-labeled BSA, as described previously (30) . In brief, EAhy926 cells were grown on the upper chamber of Transwell polycarbonate membranes (Corning) to a confluent monolayer and treated with histones in DMEM with 2% (v/v) FBS for 1 h. Permeability was then assessed by replacing the media in the upper chamber with 100 ml Evans blue-BSA and in the lower chamber with 500 ml DMEM with 4% (w/v) BSA. After 10 min, a 100 ml aliquot was taken from the lower chamber, and absorbance was measured at 650 nm using a spectrometer. In vivo permeability assay was carried out as follows: wild type C57BL/6 male mice of 22 6 0.5 g body weight were challenged with 50 mg/kg histones (nonlethal dose; i.v.) or histones + 10 mg/kg CRP for 4 h. Pulmonary edema was quantified by measuring the wet/dry weight ratio of the right lung. Wet weight was obtained immediately after euthanasia and dry weight after 4 d of drying at 60˚C.
Electrophysiology
Whole-cell currents were recorded using the perforated patch configuration from single EAhy926 cells using an Axopatch 200B amplifier (Axon Instruments) as previously described (31) . Recorded membrane currents were filtered at 5 kHz, digitized using a Digidata 1320A interface (Axon Instruments), and analyzed using pCLAMP software. Histones (20 mg/ml), CRP (250 mg/ml), or histones preincubated with CRP for 30 min were added to the extracellular solution and applied to the cell by bath superfusion. All experiments were performed at room temperature (18-22˚C).
Measurement of intracellular calcium
Intracellular Ca 2+ concentration was determined by measuring fluorescence emission at 510 nm during excitation at 340 and 380 nm according to published protocols (32) with fura 2-AM as the fluorescent probe. Fluorescence was monitored continuously using a Hitachi F-7000 fluorescence spectrometer, and intracellular Ca 2+ concentration was calculated using the software provided. Ca 2+ influx was stimulated by adding calf thymus histones to the fura 2-loaded EAhy926 cells.
Fluorescent staining
ahscFv and histones were labeled using a FluoroTag FITC conjugation kit (Sigma), and CRP was conjugated with Cy5 (GE Healthcare) separately. Free FITC or Cy5 was removed using a Sephadex G25 column. EAhy926 cells were fixed with 4% (w/v) paraformaldehyde, permeabilized with 1% (v/v) Triton X-100, and blocked with 5% (w/v) defatted milk before the costaining with 10 mg/ml FITC-ahscFv and Cy5-CRP for 1 h. Images were taken using LSM 710 confocal microscope. For histone-plasma membrane interactions, EAhy926 cells were seeded in glass-bottom dishes for 24 h and incubated with FITC-histones (10 mg/ml) alone or with CRP, denatured CRP (dCRP) (250 mg/ml), and liposomes (100 mM) made of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS). The images were taken after 10-min incubation using LSM 710 confocal microscope.
Binding assays
Gel overlay was used to determine which histones bind CRP. In brief, equal amounts of proteins were subjected to SDS-PAGE. One gel was stained with Coomassie brilliant blue to ensure equal loading and the other electroblotted onto polyvinylidence difluoride membranes, which were incubated at 4˚C overnight with 3 mg/ml CRP. Bound CRP was detected using anti-CRP-HRP (Sigma). In addition, the competitive binding of histones to CRP or phospholipids was examined by a competitive ELISA. In brief, histones were coated on ELISA plates and incubated with different doses of liposomes mixed with 50 mg/ml CRP. The bound CRP was detected with anti-CRP-HRP, and the absorbance at 450 nM was used to represent the relative amount of CRP that bound to coated histones. The liposomes were prepared as described previously (33) using PS and PE at a ratio 1:2 to reflect the ratio in plasma membrane. PC, another major phospholipid in cell membranes, was omitted to avoid the possibility of its interaction with CRP (34).
Immunohistochemical staining
Paraffin-embedded lung sections were dewaxed and rehydrated followed by Ag retrieval using DAKO PT-Pre-Treatment link system. Anti-fibrin Ab (Abcam) and EnVision+ kit (DAKO) was used to probe fibrin. Images were taken using Olympus Microscopy and Nikon ACT-1 software.
Platelet aggregation assay
Blood was withdrawn from healthy donors, and freshly isolated washed platelets (35) were treated with recombinant human histone H3 and H4 (New England Biolabs), preincubated with or without CRP. Platelet aggregation was conducted using a Born Aggregometer (pap 8, Bio-DATA).
Statistical analysis
Intergroup differences were analyzed using ANOVA followed by the Student-Newman-Keuls test. Two-group comparison before and after treatment used Student t test with animal survival time analyzed using a log-rank test. Association analysis used simple linear correlation. Mean 6 SD are from at least three independent experiments.
Results

CRP reduces histone-induced endothelial cell damage and permeability increase
Extracellular histones have been demonstrated to be toxic to endothelial cells (24) . Fig. 1A showed that calf thymus histones in culture medium with 2% (v/v) FBS are significantly toxic to cultured EAhy926 cells, a human endothelial cell line. The toxicity of 40 mg/ml histones to EAhy926 cells can be significantly reduced when CRP was .50 mg/ml (Fig. 1B) . BSA, as control, was unable to block histone toxicity to these cells (data not shown). Primary HUVECs isolated from cords were also used and showed similar responses to indicate that histone toxicity and CRP protection are not cell-line-specific effects (Fig. 1C) . Activated protein C, which can cleave histones (24) , was also used as positive control and could reduce histone toxicity in this assay.
In vivo translation of these data are shown in Fig. 1D -F. sTM, a circulating marker of endothelial damage, increased significantly in mice injected with a nonlethal infusion of histones at 50 mg/kg. When this was coinjected with 10 mg/kg CRP, sTM levels decreased significantly (Fig. 1D) . Because the immediate consequence of endothelial damage is an increase in vascular permeability, preincubation with CRP was able to reduce significantly histoneinduced permeability in vitro (Fig. 1E) and in vivo (Fig. 1F) . Collectively, these data indicate that CRP can inhibit extracellular histone-induced endothelial damage and its consequences.
CRP inhibits histone-induced platelet aggregation and coagulation activation CRP significantly inhibited histone-induced platelet aggregation by up to 50% but did not block it completely even at a very high concentration of 250 mg/ml (Fig. 2A, 2B ). In mice, coinfusion of CRP (10 mg/kg) partially alleviated thrombocytopenia induced by injection of 60 mg/kg histones (Fig. 2C) . Activation of coagulation, as measured by TAT complexes, was also significantly reduced in mice injected with 50 mg/kg histones + 10 mg/kg CRP compared with histone treatment alone (Fig. 2D) . These data strongly indicate that CRP is able to attenuate histone-induced platelet and thrombin activation. The significant but incomplete blockage of these effects by CRP might serve to retain vital hemostatic processes whereas limiting excessive histone-induced damage at sites of vascular injury.
CRP protects mice challenged with lethal doses of histones by reducing lung edema, hemorrhage, and thrombosis A total of 75 mg/kg histones killed all mice within an hour. Survival times were prolonged with one in seven mice surviving for .6 d when low-dose CRP (1.6 mg/kg) was coinfused. When CRP level was increased to 5 mg/kg, 3 of 7 mice survived for .6 d and 4 of 7 mice died between 7 and 11 h. At 10 mg/kg CRP, all seven mice survived .6 d (Fig. 3A) . A log-rank test showed significant differ- ences in survival times among the four groups (p , 0.001). Histological examination showed that mice that died at 1 h after injection of 75 mg/kg histones alone had obvious lung edema and hemorrhage (Fig. 3Bb) , but mice euthanized 1 h after injection of 75 mg/kg histones + 10 mg/kg CRP had less edema and hemorrhage, although congestion and increased alveolar wall thickness were observed (Fig. 3Bc) . Immunohistochemical staining for fibrin showed obvious thrombosis in lungs from mice injected with 75 mg/kg histones alone (Fig. 3Be) , but not in mice injected with histones preincubated with 10 mg/kg CRP. However, fibrin deposition was clearly observed in lungs (Fig. 2Bf) . These pathological changes support the finding that CRP reduces histone-induced endothelial damage and coagulation activation.
Acute CRP elevation in patients reduces histone toxicity to endothelial cells
When serum samples from patients with severe trauma were incubated with endothelial cells, those collected within 4 h of injury could induce significant cell death (Fig. 4A) . However, this effect was not observed at later time points of 24 and 72 h despite histone levels remaining elevated. The functional difference could be because of endogenous CRP levels, which were not raised within 4 h but were .150 mg/ml at 24 and 72 h after trauma. Indeed, this corresponded to significant elevation of CRP-histone complex levels, but only at 24 and 72 h (Fig. 4B ). These data suggest that CRP is a major factor in combating histone-induced toxicity in patients.
To confirm this, we collected sera from patients with necrotizing pancreatitis (Fig. 4C ) and severe sepsis (Fig. 4D) , which are conditions also associated with extensive cell damage. Sera that contained high histone levels but low CRP concentrations were toxic to endothelial cells, whereas sera that were high in both CRP and histones were much less toxic. If exogenous CRP was added to sera with high histone levels, their toxic effects could be attenuated. These data indicate that elevated CRP is able to reduce clinically toxicity of circulating histones.
The mechanism of CRP detoxification is through preventing histone-cell membrane interaction by complex formation
We previously showed that histone-induced toxicity relied on membrane interaction and calcium influx (27) . Preincubation of histones with CRP significantly reduced cell membrane association of FITC-labeled histones (Fig. 5A) , as well as histone-induced inward currents (Fig. 5B, 5C ) and calcium influx (Fig. 5D, 5E ). These data strongly indicate that masking the membrane binding sites of histones is the mechanism of CRP detoxification.
The proposed mechanism of histone-cell membrane interaction is their affinity to phosphate groups of major phospholipids in the cell membrane, such as PC, PS, and PE (27, 36, 37) , because phosphate groups exist in both DNA and bilayer lipid membranes. Preincubation of FITC-labeled histones with liposomes made of PC, PS, and PE significantly reduced the binding of histones to the cell membrane (Fig. 6A) . Functionally, this significantly reduced the toxic effects of histones on endothelial cells (Fig. 6B) . These data support the hypothesis that phospholipids on cell membranes are the major targets of histones.
It is also known that CRP binds to the phosphocholine group of lysoPC (34) . However, lysoPC is exposed only after the lipid bilayer of cell membranes has been disturbed, such as during necrosis and apoptosis (38) . Therefore, CRP does not bind to normal cell membranes. In this study, we found that incubating CRP with EAhy926 cells for 1-4 h did not reduce histone-induced toxicity if CRP were washed away before histone treatment (data not shown). This experiment also indicates that CRP prevention of histone-membrane interaction is not due to CRP association with cell membranes.
In line with our findings of the existence of circulating CRPhistone complexes, the interaction between CRP and histone has been reported previously but with some discrepant findings (13, 14, (39) (40) (41) . To clarify these discrepancies, we immunofluorescently stained EAhy926 cells with Cy5-CRP and FITC-ahscFv to avoid any nonspecific staining of IgGs. Their colocalization observed in cell nuclei strongly indicates that CRP binds to histones (Fig. 6C) . Furthermore, a gel overlay assay showed that all histones could bind CRP (Fig. 6D) and that CRP could protect endothelial cells treated with the individual histones (Fig. 6E) . Using competitive ELISA, we found that CRP competed with liposomes in binding histones (Fig. 6F, 6G ) to explain how CRP blocks histone-plasma membrane integration (Fig. 5A ).
Discussion
The acute-phase response is a complex series of reactions initiated in response to infection, inflammation, injury, or malignancy. Elevation in CRP levels has long been recognized in this context, but despite many reports into its properties, clear understanding of its generic function has been lacking (42). In part, this is because no mutation of this phylogenetically ancient and well-conserved molecule has been described, although a few nucleotide polymorphisms that do not alter the protein sequence have been identified (43) . This would suggest a critical functional role for CRP. Although the concept of CRP acting to detoxify and clear damaging products of cell destruction was hypothesized back in 1981 (44) , this study demonstrates for the first time, to our knowledge, that high levels of CRP in the acute clinical phase plays a major role in combating the toxicity of circulating histones. H4 ) and 6 mg S100P protein (negative control) were subjected to a gel overlay assay with 3 mg/ml CRP. Coomassie blue stained gel (upper panel) shows the gel loading (n = S100P multimer, m = S100P monomer). Overlaid with CRP and detected with anti-CRP Ab (lower panel). (E) CRP protection of EAhy926 cells treated with 40 mg/ml individual human recombinant histones in the presence (white) or absence (black) of 250 mg/ml CRP. Means 6 SD from four independent experiments are shown; *p , 0.05 in cell survival compared with untreated (UT), # p # 0.035 in relation to CRP addition (Student t test). (F) Competitive ELISA assay to demonstrate that CRP and phospholipids (PE+PS) competitively interact with histones. ELISA plates were coated with histones or buffer alone and incubated with 2 mM liposomes made of PS+PE (1:2) mixed with 50 mg/ml CRP. After washing, the bound CRP was detected using anti-CRP-HRP. Means 6 SD of the absorbance from three independent experiments are shown. *p , 0.001 compared with other groups (ANOVA), # p = 0.007 compared with group 1 (Student t test). (G) A typical dose-response curve of the competitive ELISA with 0-200 mM liposomes. The bound CRP was detected using anti-CRP-HRP, and the means of absorbance from three independent experiments are presented.
In this study, we demonstrate that CRP could significantly alleviate histone-induced endothelial damage and coagulation activation, which are the major toxic effects of extracellular histones. CRP protective effects are due to its interaction with histones, and this has been further confirmed by coimmunofluorescent staining and gel overlay assay. How CRP binds histones is not clear, but positively charged histones are more likely to bind the predominantly negatively charged central pore of the CRP pentamer in a similar way to that of complement C1q. Because complement factor H has been reported to bind dCRP (nonnative pentameric CRP), we also denatured CRP by heating at 70˚C for 1 h as described in a previous report (4) . The dCRP strongly aggregated with FITC-labeled histones, and greatly reduced the binding of histones to the cell membrane and reduced histone toxicity to endothelial cells (Supplemental Fig. 1 ) These data indicate that both native and nonnative pentameric CRP are able to bind histones and reduce their toxic effects.
Because histones released after acute cellular and nuclear damage may also be present in the form of histone-DNA complexes, we have additionally checked their toxicity profile and any blocking effect by CRP. Using isolated nucleosomes (Supplemental Fig. 2A-C) and histones from swine liver, prepared as described previously (45), we demonstrate that swine histones have similar toxicity to cultured endothelial cells as with recombinant or calf thymus histones (data not shown). However, intact nucleosomes are not toxic (Supplemental Fig. 2D ), but degraded nucleosomes, either from brief sonication or incubation with serum, showed toxicity to endothelial cells. Significantly, this could be reduced by CRP and dCRP (Supplemental Fig. 2D ). To confirm this finding, genomic DNA fragments were mixed with isolated histones to create artificial histone-DNA complexes, as described previously (25) . Again, we found that the complexes showed similar toxicity to histones alone, but that DNA alone was not toxic (Supplementary Fig. 3 ). These data suggest that the toxicity of histone-DNA complexes to endothelial cells is predominantly caused by histones, although histone-DNA complexes are stronger activators of TLR2 and TLR4 receptors and subsequent release of cytokines than histones alone (25) . Similarly, CRP or dCRP can significantly reduce this toxicity (Supplementary Fig 3) . As to the clinical implications, our previous study has shown that circulating histone-DNA complexes were detectable only within 24 h after severe trauma, and that free histones remain detectable after 72 h (27) . This suggests that histone-DNA complexes have been quickly degraded into histones. Collectively, these data would indicate that in vivo toxicity is caused by both histone-DNA complexes and histones alone in the circulation, and that CRP can block both forms, as confirmed by adding CRP to serum from patients in the immediate phases after severe trauma (Fig. 4A) .
As to the mechanism of histone toxicity, a previous report showed that histones increased cell membrane permeability (46) , but a recent report showed that anti-TLR4 or anti-TLR2 Ab could rescue mice from fatal liver injury to suggest that TLR4 and TLR2 may be involved in histone toxicity (25) . We demonstrate that histones integrate onto the endothelial cell membrane both in vitro and in vivo to induce calcium influx, which is essential for histone toxicity, at least to endothelial cells (27) and platelets (22) . CRP protection relies on the formation of CRP-histone complexes, which prevents the integration of histones into the cell membrane and consequently reduced histone-induced calcium influx and cell damage. We also found the aggregation of FITC-labeled histones after incubation with CRP both in tissue culture medium and inside cells. Whether CRP enhances the clearance of circulating histones still requires further investigation.
Histones can bind different phospholipids (36, 37, 47, 48) , and as these are major components of the cell membrane, we speculate that histones bind to the phospholipid bilayer in the plasma membrane in a manner similar to the interaction between the DNA phosphodiester backbone and the histone cores (49) . In this study, we demonstrate that artificial liposomes made of phospholipids compete with the cell membranes for histone binding and significantly reduce histone-induced toxicity. CRP is also able to compete with phospholipids for binding to histones, and this indicates that the major mechanism underlying the protective effects of CRP in vitro and in vivo is in its interference with the histone association to cell membranes. Therefore, CRP binds histones, as in its role in opsonizing pathogens, to block their toxic effect on cells and to possibly facilitate their clearance. This action defends the human body from the toxicity of circulating histones, especially in the acute phase of many critical illnesses.
